2026-10-11T19:37:20Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33717847 2026-09-14T04:31:42Z category_696 portal_316 item_type_3 month_year_09_2026

Data Sheet 2_A neuroimmune-enriched multibiofluid proteomic index associated with cognitive-motor progression in early Parkinson’s disease: a longitudinal PPMI cohort study.xlsx Hao Wang (39217) Guoqing Wu (4029752) Dengke Zhang (3703843) Wanjun Feng (420334) Xuebin Zhao (735578) Weixiong Zhang (10203) Ganqin Du (24280674) Genetic Immunology cognitive impairment motor progression neuroimmune-enriched multibiofluid proteomic index neuroimmunology Parkinson’s disease PD-MCI PPMI (Parkinson’s Progression Markers Initiative) proteomics <p>Progression in early Parkinson's disease (PD) is heterogeneous, motivating transparent biological markers of group-level progression context. We analyzed longitudinal Parkinson’s Progression Markers Initiative (PPMI) data downloaded on 31 May 2026. The neuroimmune-enriched multibiofluid proteomic index (NEMPI) used 718 quality-control-eligible cerebrospinal fluid and plasma markers, organized into four source-context modules with equal marker and module weights. Direct normalized protein quantification (NPQ) z-standardization was used for the primary reporting implementation, with the log1p implementation examined as a preprocessing sensitivity analysis. Among the 521 participants in the same-sample Cox comparison (173 first observed cognitive-status abnormalities), adding NEMPI to demographic, clinical, alpha-synuclein seed amplification assay, dopamine-transporter imaging, and apolipoprotein E (APOE) epsilon4 covariates yielded an NEMPI hazard ratio (HR) of 1.287 per 1-SD higher value (95% confidence interval (CI): 1.102–1.502; P = 0.001) and improved likelihood-based fit, but the C-index increment was small (0.0032; bootstrap 95% CI: -0.0093 to 0.0239). The consecutive-abnormality association was stronger but had fewer events, with fewer than 10 events per parameter; the persistent/irreversible estimate was weaker, and its confidence interval crossed 1. Higher NEMPI was also associated with a modest group-average Montreal Cognitive Assessment (MoCA) and motor trajectory differences, with 5-year translations below published minimal clinically important difference (MCID) ranges. Results were similar under 5-year censoring, discrete-time analysis, stabilized inverse-probability weighting, age analyses, and measured confounder or preanalytic adjustments. NEMPI is therefore interpreted as an abundance-based, neuroimmune-enriched, multibiofluid proteomic composite associated with broad cognitive-motor progression, not as a patient-level prediction tool, clinical threshold, cognition-specific biomarker, or causal mechanism.</p> 2026-09-14T04:31:42Z Dataset Dataset 10.3389/fimmu.2026.1928940.s001 https://figshare.com/articles/dataset/Data_Sheet_2_A_neuroimmune-enriched_multibiofluid_proteomic_index_associated_with_cognitive-motor_progression_in_early_Parkinson_s_disease_a_longitudinal_PPMI_cohort_study_xlsx/33717847 CC BY 4.0